Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellu Tears Ultra is an ophthalmic lubricant formulation developed by Grevis Pharma. It is a fixed-dose combination of carboxymethylcellulose sodium and glycerin, designed to provide temporary relief from burning, irritation, and discomfort caused by dry eyes. Carboxymethylcellulose sodium acts as a mucoadhesive lubricant that increases tear viscosity and stabilizes the tear film, while glycerin serves as an ophthalmic demulcent that lubricates the mucous membrane surface of the eye. Together, these active ingredients help restore natural moisture and protect the ocular surface from further irritation or damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylcellulose sodium + glycerin (Grevis Pharmaceuticals).